Melanoma risk prediction based on a polygenic risk score and clinical risk factors.
Journal
Melanoma research
ISSN: 1473-5636
Titre abrégé: Melanoma Res
Pays: England
ID NLM: 9109623
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
medline:
5
7
2023
pubmed:
25
4
2023
entrez:
25
04
2023
Statut:
ppublish
Résumé
Melanoma is one of the most commonly diagnosed cancers in the Western world: third in Australia, fifth in the USA and sixth in the European Union. Predicting an individual's personal risk of developing melanoma may aid them in undertaking effective risk reduction measures. The objective of this study was to use the UK Biobank to predict the 10-year risk of melanoma using a newly developed polygenic risk score (PRS) and an existing clinical risk model. We developed the PRS using a matched case-control training dataset ( N = 16 434) in which age and sex were controlled by design. The combined risk score was developed using a cohort development dataset ( N = 54 799) and its performance was tested using a cohort testing dataset ( N = 54 798). Our PRS comprises 68 single-nucleotide polymorphisms and had an area under the receiver operating characteristic curve of 0.639 [95% confidence interval (CI) = 0.618-0.661]. In the cohort testing data, the hazard ratio per SD of the combined risk score was 1.332 (95% CI = 1.263-1.406). Harrell's C-index was 0.685 (95% CI = 0.654-0.715). Overall, the standardized incidence ratio was 1.193 (95% CI = 1.067-1.335). By combining a PRS and a clinical risk score, we have developed a risk prediction model that performs well in terms of discrimination and calibration. At an individual level, information on the 10-year risk of melanoma can motivate people to take risk-reduction action. At the population level, risk stratification can allow more effective population-level screening strategies to be implemented.
Identifiants
pubmed: 37096571
doi: 10.1097/CMR.0000000000000896
pii: 00008390-202308000-00004
pmc: PMC10309112
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
293-299Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005; 41:45–60.
Grob JJ, Gouvernet J, Aymar D, Mostaque A, Romano MH, Collet AM, et al. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. Cancer 1990; 66:387–395.
Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005; 41:2040–2059.
Olsen CM, Pandeya N, Thompson BS, Dusingize JC, Green AC, Neale RE, et al.; QSkin Study. Association between phenotypic characteristics and melanoma in a large prospective cohort study. J Invest Dermatol 2019; 139:665–672.
Ford D, Bliss JM, Swerdlow AJ, Armstrong BK, Franceschi S, Green A, et al. Risk of cutaneous melanoma associated with a family history of the disease. The International Melanoma Analysis Group (IMAGE). Int J Cancer 1995; 62:377–381.
Usher-Smith JA, Emery J, Kassianos AP, Walter FM. Risk prediction models for melanoma: a systematic review. Cancer Epidemiol Biomarkers Prev 2014; 23:1450–1463.
Vuong K, Armstrong BK, Weiderpass E, Lund E, Adami HO, Veierod MB, et al.; Australian Melanoma Family Study Investigators. Development and external validation of a melanoma risk prediction model based on self-assessed risk factors. JAMA Dermatol 2016; 152:889–896.
Vuong K, Armstrong BK, Drummond M, Hopper JL, Barrett JH, Davies JR, et al. Development and external validation study of a melanoma risk prediction model incorporating clinically assessed naevi and solar lentigines. Br J Dermatol 2020; 182:1262–1268.
Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, et al.; Nordic Twin Study of Cancer (NorTwinCan) Collaboration. Familial risk and heritability of cancer among twins in nordic countries. JAMA 2016; 315:68–76.
Wei EX, Li X, Nan H. Having a first-degree relative with melanoma increases lifetime risk of melanoma, squamous cell carcinoma, and basal cell carcinoma. J Am Acad Dermatol 2019; 81:489–499.
Frank C, Fallah M, Sundquist J, Hemminki A, Hemminki K. Population landscape of familial cancer. Sci Rep 2015; 5:12891.
Truderung OA, Sagi JC, Semsei AF, Szalai C. Melanoma susceptibility: an update on genetic and epigenetic findings. Int J Mol Epidemiol Genet 2021; 12:71–89.
Lewis CM, Vassos E. Polygenic risk scores: from research tools to clinical instruments. Genome Med 2020; 12:44.
Potjer TP, van der Grinten TWJ, Lakeman IMM, Bollen SH, Rodríguez-Girondo M, Iles MM, et al. Association between a 46-SNP polygenic risk score and melanoma risk in Dutch patients with familial melanoma. J Med Genet 2021; 58:760–766.
Bakshi A, Yan M, Riaz M, Polekhina G, Orchard SG, Tiller J, et al. Genomic risk score for melanoma in a prospective study of older individuals. J Natl Cancer Inst 2021; 113:1379–1385.
Cust AE, Drummond M, Kanetsky PA, Barrett JH, MacGregor S, Law MH, et al.; Australian Melanoma Family Study Investigators. Assessing the incremental contribution of common genomic variants to melanoma risk prediction in two population-based studies. J Invest Dermatol 2018; 138:2617–2624.
Curtis D. Clinical relevance of genome-wide polygenic score may be less than claimed. Ann Hum Genet 2019; 83:274–277.
Gu F, Chen T-H, Pfeiffer RM, Fargnoli MC, Calista D, Ghiorzo P, et al. Combining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma. Hum Mol Genet 2018; 27:4145–4156.
Steinberg J, Iles MM, Lee JY, Wang X, Law MH, Smit AK, et al. Independent evaluation of melanoma polygenic risk scores in UK and Australian prospective cohorts. Br J Dermatol 2022; 186:823–834.
Landi MT, Bishop DT, MacGregor S, Machiela MJ, Stratigos AJ, Ghiorzo P, et al.; GenoMEL Consortium. Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nat Genet 2020; 52:494–504.
Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 2015; 12:e1001779.
Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 2018; 562:203–209.
Privé F, Vilhjálmsson BJ, Aschard H, Blum MGB. Making the most of clumping and thresholding for polygenic scores. Am J Hum Genet 2019; 105:1213–1221.
Prive F, Aschard H, Ziyatdinov A, Blum MGB. Efficient analysis of large-scale genome-wide data with two R packages: bigstatsr and bigsnpr. Bioinformatics 2018; 34:2781–2787.
Yu Y, Hu H, Chen J-S, Hu F, Fowler J, Scheet P, et al. Integrated case-control and somatic-germline interaction analyses of melanoma susceptibility genes. Biochim Biophys Acta Mol Basis Dis 2018; 1864:2247–2254.
Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V, et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011; 480:99–103.
Potrony M, Puig-Butille JA, Aguilera P, Badenas C, Tell-Marti G, Carrera C, et al. Prevalence of MITF p.E318K in patients with melanoma independent of the presence of CDKN2A causative mutations. JAMA Dermatol 2016; 152:405–412.
Raimondi S, Sera F, Gandini S, Iodice S, Caini S, Maisonneuve P, et al. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int J Cancer 2008; 122:2753–2760.
Nan H, Xu M, Kraft P, Qureshi AA, Chen C, Guo Q, et al. Genome-wide association study identifies novel alleles associated with risk of cutaneous basal cell carcinoma and squamous cell carcinoma. Hum Mol Genet 2011; 20:3718–3724.
Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Ebell M, Epling JW, et al.; US Preventive Services Task Force. Screening for skin cancer US preventive services task force recommendation statement. JAMA 2016; 316:429–435.
Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical practice guidelines for the management of melanoma in Australia and New Zealand. The Cancer Council Australia and Australian Cancer Network, Sydney and New Zealand Guidelines Group, Wellington; 2008. https://www.health.govt.nz/publication/clinical-practice-guidelines-management-melanoma-australia-and-new-zealand . [Accessed 20 July 2022].
Marsden JR, Newton-Bishop JA, Burrows L, Cook M, Corrie PG, Cox NH, et al.; British Association of Dermatologists (BAD) Clinical Standards Unit. Revised UK guidelines for the management of cutaneous melanoma 2010. J Plast Reconstr Aesthet Surg 2010; 63:1401–1419.
Katalinic A, Eisemann N, Waldmann A. Skin cancer screening in Germany. Documenting melanoma incidence and mortality from 2008 to 2013. Dtsch Arztebl Int 2015; 112:629–634.
German Guideline Program in Oncology (GGPO). Evidence-based guideline on prevention of skin cancer (short version). https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Hautkrebspraeventationsleitlinie_1.1/Short_version_-_Guideline_on_prevention_of_skin_cancer.pdf . [Accessed 20 July 2022].
Ribero S, Longo C, Glass D, Nathan P, Bataille V. What is new in melanoma genetics and treatment? Dermatology 2016; 232:259–264.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) Genetic/familial high-risk assessment: breast, ovarian, and pancreatic version 2.2022.
Begg CB, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, et al.; Genes Environment and Melanoma Study Group. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 2005; 97:1507–1515.
Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005; 41:28–44.
Olsen CM, Carroll HJ, Whiteman DC. Familial melanoma: a meta-analysis and estimates of attributable fraction. Cancer Epidemiol Biomarkers Prev 2010; 19:65–73.
Goldenberg A, Vujic I, Sanlorenzo M, Ortiz-Urda S. Melanoma risk perception and prevention behavior among African-Americans: the minority melanoma paradox. Clin Cosmet Investig Dermatol 2015; 8:423–429.
Mahendraraj K, Sidhu K, Lau CSM, McRoy GJ, Chamberlain RS, Smith FO. Malignant melanoma in African-Americans: a population-based clinical outcomes study involving 1106 African-American patients from the surveillance, epidemiology, and end result (SEER) database (1988-2011). Medicine (Baltimore) 2017; 96:e6258.
Gordon LG, Leung W, Johns R, McNoe B, Lindsay D, Merollini KMD, et al. Estimated healthcare costs of melanoma and Keratinocyte skin cancers in Australia and aotearoa New Zealand in 2021. Int J Environ Res Public Health 2022; 19:3178.